Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority
Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME)
Remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual acuity compared with anti-VEGF therapy in a pivotal DME trial
Despite available therapies, up to 40% of people with DME have persistent disease after six months, driving need for new approaches
Login to comment